Amneal Pharmaceuticals Inc - Class A

Research Amneal Pharmaceuticals Inc - Class A (AMRX) on Bullrun: valuation model: 31.8% overvalued, market cap USD 5.52B, P/E 46.4. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAMRX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryDrug Manufacturers-Specialty & Generic
• CurrencyUSD
• Valuation signal31.8% overvalued
• Market capUSD 5.52B
• P/E46.4
• Financial periodFY2025
• RevenueUSD 3.02B
• Revenue growth8.0%
• Net incomeUSD 72.06M
• Free cash flowUSD 269.93M
• Gross margin36.9%

Valuation Snapshot

Bullrun's latest valuation model marks Amneal Pharmaceuticals Inc - Class A as 31.8% overvalued; latest market cap is USD 5.52B; P/E is 46.4.

About Amneal Pharmaceuticals Inc - Class A

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Frequently asked questions

Is Amneal Pharmaceuticals Inc - Class A overvalued or undervalued?

Bullrun's valuation model currently marks Amneal Pharmaceuticals Inc - Class A as 31.8% overvalued.

What is Amneal Pharmaceuticals Inc - Class A's market cap?

Amneal Pharmaceuticals Inc - Class A's market capitalization is USD 5.52B.

What is Amneal Pharmaceuticals Inc - Class A's P/E ratio?

Amneal Pharmaceuticals Inc - Class A's price-to-earnings (P/E) ratio is 46.4.

What does Amneal Pharmaceuticals Inc - Class A do?

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.